NKTR vs. URGN

Last updated Apr 2, 2026

Compare and contrast key facts about Nektar Therapeutics (NKTR) and UroGen Pharma Ltd. (URGN).

Performance

NKTR vs. URGN - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Nektar Therapeutics (NKTR) and UroGen Pharma Ltd. (URGN). The values are adjusted to include any dividend payments, if applicable.

NKTR vs. URGN - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
NKTR Nektar Therapeutics	79.07%	203.08%	64.60%	-75.00%	-83.27%	-20.53%	-21.26%	-34.32%	-44.96%	221.42%
URGN UroGen Pharma Ltd.	-19.13%	119.91%	-29.00%	69.11%	-6.73%	-47.23%	-46.00%	-22.50%	15.72%	166.17%

Fundamentals

Market Cap NKTR : $1.54B URGN : $932.42M
EPS NKTR : -$10.15 URGN : -$3.18
PS Ratio NKTR : 22.15 URGN : 8.34
Total Revenue (TTM) NKTR : $55.23M URGN : $109.79M
Gross Profit (TTM) NKTR : $55.04M URGN : $97.34M
EBITDA (TTM) NKTR : -$122.97M URGN : -$127.69M

Returns By Period

In the year-to-date period, NKTR achieves a 79.07% return, which is significantly higher than URGN's -19.13% return.

NKTR

• 1D: 5.23%
• 1M: 10.75%
• YTD: 79.07%
• 6M: 28.65%
• 1Y: 691.99%
• 3Y*: 92.93%
• 5Y*: -24.37%
• 10Y*: -9.98%

URGN

• 1D: 5.34%
• 1M: -0.42%
• YTD: -19.13%
• 6M: 6.31%
• 1Y: 78.17%
• 3Y*: 27.03%
• 5Y*: -0.71%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

NKTR vs. URGN — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NKTR

NKTR Risk / Return Rank: 99
NKTR Sharpe Ratio Rank: 98
NKTR Sortino Ratio Rank: 99
NKTR Omega Ratio Rank: 98
NKTR Calmar Ratio Rank: 99
NKTR Martin Ratio Rank: 99

URGN

URGN Risk / Return Rank: 69
URGN Sharpe Ratio Rank: 65
URGN Sortino Ratio Rank: 73
URGN Omega Ratio Rank: 76
URGN Calmar Ratio Rank: 64
URGN Martin Ratio Rank: 66

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

NKTR vs. URGN - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Nektar Therapeutics (NKTR) and UroGen Pharma Ltd. (URGN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	NKTR	URGN	Difference
Sharpe ratio Return per unit of total volatility	3.69	0.69	+3.00
Sortino ratio Return per unit of downside risk	5.91	1.78	+4.14
Omega ratio Gain probability vs. loss probability	1.67	1.27	+0.40
Calmar ratio Return relative to maximum drawdown	13.80	1.08	+12.73
Martin ratio Return relative to average drawdown	33.65	3.00	+30.66
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

NKTR vs. URGN - Sharpe Ratio Comparison

The current NKTR Sharpe Ratio is 3.69, which is higher than the URGN Sharpe Ratio of 0.69. The chart below compares the historical Sharpe Ratios of NKTR and URGN, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	NKTR	URGN	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	3.69	0.69	+3.00
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.20	-0.01	-0.19
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.10	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.01	0.04	-0.03

Correlation

The correlation between NKTR and URGN is 0.26, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

NKTR vs. URGN - Dividend Comparison

Neither NKTR nor URGN has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

NKTR vs. URGN - Drawdown Comparison

The maximum NKTR drawdown since its inception was -99.61%, which is greater than URGN's maximum drawdown of -93.98%. Use the drawdown chart below to compare losses from any high point for NKTR and URGN.

Drawdown Indicators

	NKTR	URGN	Difference
Max Drawdown Largest peak-to-trough decline	-99.61%	-93.98%	-5.63%
Max Drawdown (1Y) Largest decline over 1 year	-46.54%	-66.24%	+19.70%
Max Drawdown (5Y) Largest decline over 5 years	-97.93%	-82.64%	-15.29%
Max Drawdown (10Y) Largest decline over 10 years	-99.61%	—	—
Current Drawdown Current decline from peak	-95.35%	-71.01%	-24.34%
Average Drawdown Average peak-to-trough decline	-68.17%	-61.55%	-6.62%
Ulcer Index Depth and duration of drawdowns from previous peaks	19.09%	23.79%	-4.70%

Volatility

NKTR vs. URGN - Volatility Comparison

Nektar Therapeutics (NKTR) has a higher volatility of 17.64% compared to UroGen Pharma Ltd. (URGN) at 15.35%. This indicates that NKTR's price experiences larger fluctuations and is considered to be riskier than URGN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	NKTR	URGN	Difference
Volatility (1M) Calculated over the trailing 1-month period	17.64%	15.35%	+2.29%
Volatility (6M) Calculated over the trailing 6-month period	65.68%	49.37%	+16.31%
Volatility (1Y) Calculated over the trailing 1-year period	189.39%	113.74%	+75.65%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	121.48%	91.48%	+30.00%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	96.96%	79.73%	+17.23%

Financials